Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter]

on behalf of the VERTIS CV Investigators

doi:10.1007/s00125-021-05623-z

Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter]

on behalf of the VERTIS CV Investigators

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	908-911
Number of pages	4
Journal	Diabetologia
Volume	65
Issue number	5
DOIs	https://doi.org/10.1007/s00125-021-05623-z
State	Published - May 2022

Keywords

Body weight
Chronic kidney disease
Ertugliflozin
Estimated glomerular filtration rate
Kidney outcomes
Sodium–glucose cotransporter 2 inhibitor

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism

Access to Document

10.1007/s00125-021-05623-z

Cite this

@article{70ea940b5a39460baa31a9cf423e76c2,

title = "Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter]",

keywords = "Body weight, Chronic kidney disease, Ertugliflozin, Estimated glomerular filtration rate, Kidney outcomes, Sodium–glucose cotransporter 2 inhibitor",

author = "{on behalf of the VERTIS CV Investigators} and Cherney, {David Z.I.} and Bernard Charbonnel and Francesco Cosentino and Samuel Dagogo-Jack and McGuire, {Darren K.} and Richard Pratley and Shih, {Weichung J.} and Robert Frederich and Mario Maldonado and Annpey Pong and Cannon, {Christopher P.}",

note = "Funding Information: The authors would like to thank the participants, their families and all investigators involved in the VERTIS CV study; the list of investigators can be found with the primary publication [11]. Medical writing and/or editorial assistance was provided by M. Hammad and I. Norton, both of Scion (London, UK). This assistance was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., (Kenilworth, NJ, USA) and Pfizer Inc. (New York, NY, USA). DZIC has received consulting fees or speaking honorarium, or both, from Bristol-Myers Squibb, Novo Nordisk, Mitsubishis-Tanabe, MAZE, Janssen, Bayer, Boehringer Ingelheim, Eli Lilly, AstraZeneca, Merck & Co., Inc., Prometic and Sanofi, and has received operating funds from Janssen, Boehringer Ingelheim-Eli Lilly, Sanofi, AstraZeneca, Novo Nordisk and Merck & Co., Inc., Prometic and Sanofi, and has received operating funds from Janssen, Boehringer Ingelheim, Eli Lilly, Sanofi, AstraZeneca and Merck & Co., Inc. BC has received fees for the following activities: advisory boards for AstraZeneca, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (Kenilworth, NJ, USA), Novo Nordisk, Sanofi and Servier; and speaker bureau for AstraZeneca, Eli Lilly, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (Kenilworth, NJ, USA), Novo Nordisk, Sanofi and Takeda. FC has received fees from Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Merck Sharp & Dohme, Novo Nordisk and Pfizer, as well as research grants from Swedish Research Council, Swedish Heart & Lung Foundation and the King Gustav V and Queen Victoria Foundation. SD-J has led clinical trials for AstraZeneca, Novo Nordisk, Inc. and Boehringer Ingelheim, has received fees from AstraZeneca, Boehringer Ingelheim, Janssen, Merck & Co., Inc. and Sanofi, and holds equity interests in Jana Care, Inc. and Aerami Therapeutics. DKM has had leadership roles in clinical trials for AstraZeneca, Boehringer Ingelheim, CSL Behring, Eisai, Esperion, GlaxoSmithKline, Janssen, Lexicon, Merck & Co., Inc., Novo Nordisk and Sanofi USA, and has received consultancy fees from AstraZeneca, Bayer, Boehringer Ingelheim, Lilly USA, Merck & Co., Inc., Pfizer, Novo Nordisk, Metavant, Afimmune and Sanofi. RP has received the following fees (directed to his institution): speaker fees from Novo Nordisk; consulting fees from Merck & Co., Inc., Novo Nordisk, Pfizer, Sanofi, Scohia Pharma Inc. and Sun Pharmaceutical Industries; and grants from Lexicon Pharmaceuticals, Hanmi Pharmaceuticals Co., Novo Nordisk, Poxel SA and Sanofi. WJS has received fees for membership of the ertugliflozin advisory board of Merck & Co., Inc. (Kenilworth, NJ, USA). RF is an employee and shareholder of Pfizer Inc. MM is an employee of MSD UK, and may own stock and/or stock options in Merck & Co., Inc. (Kenilworth, NJ, USA). AP is an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (Kenilworth, NJ, USA) and may own stock and/or stock options in Merck & Co., Inc. (Kenilworth, NJ, USA). CPC reports grants and personal fees from Pfizer Inc. and from Merck & Co., Inc., during the conduct of the study. CPC also reports grants and personal fees from Amgen, Boehringer Ingelheim, Bristol-Myers Squibb and Janssen, grants from Better Therapeutics, Daiichi Sankyo Novo Nordisk, and personal fees from Aegerion/Amryt, Alnylam, Amarin, Applied Therapeutics, Ascendia, Corvidia, HLS Therapeutics, Innovent, Kowa, Sanofi, Eli Lilly, Lexicon, Rhoshan, and Sanofi outside the submitted work. CPC serves on Data and Safety Monitoring Boards for the Veterans Administration, Applied Therapeutics and Novo Nordisk. Funding Information: DZIC has received consulting fees or speaking honorarium, or both, from Bristol-Myers Squibb, Novo Nordisk, Mitsubishis-Tanabe, MAZE, Janssen, Bayer, Boehringer Ingelheim, Eli Lilly, AstraZeneca, Merck & Co., Inc., Prometic and Sanofi, and has received operating funds from Janssen, Boehringer Ingelheim-Eli Lilly, Sanofi, AstraZeneca, Novo Nordisk and Merck & Co., Inc., Prometic and Sanofi, and has received operating funds from Janssen, Boehringer Ingelheim, Eli Lilly, Sanofi, AstraZeneca and Merck & Co., Inc. BC has received fees for the following activities: advisory boards for AstraZeneca, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (Kenilworth, NJ, USA), Novo Nordisk, Sanofi and Servier; and speaker bureau for AstraZeneca, Eli Lilly, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (Kenilworth, NJ, USA), Novo Nordisk, Sanofi and Takeda. FC has received fees from Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Merck Sharp & Dohme, Novo Nordisk and Pfizer, as well as research grants from Swedish Research Council, Swedish Heart & Lung Foundation and the King Gustav V and Queen Victoria Foundation. SD-J has led clinical trials for AstraZeneca, Novo Nordisk, Inc. and Boehringer Ingelheim, has received fees from AstraZeneca, Boehringer Ingelheim, Janssen, Merck & Co., Inc. and Sanofi, and holds equity interests in Jana Care, Inc. and Aerami Therapeutics. DKM has had leadership roles in clinical trials for AstraZeneca, Boehringer Ingelheim, CSL Behring, Eisai, Esperion, GlaxoSmithKline, Janssen, Lexicon, Merck & Co., Inc., Novo Nordisk and Sanofi USA, and has received consultancy fees from AstraZeneca, Bayer, Boehringer Ingelheim, Lilly USA, Merck & Co., Inc., Pfizer, Novo Nordisk, Metavant, Afimmune and Sanofi. RP has received the following fees (directed to his institution): speaker fees from Novo Nordisk; consulting fees from Merck & Co., Inc., Novo Nordisk, Pfizer, Sanofi, Scohia Pharma Inc. and Sun Pharmaceutical Industries; and grants from Lexicon Pharmaceuticals, Hanmi Pharmaceuticals Co., Novo Nordisk, Poxel SA and Sanofi. WJS has received fees for membership of the ertugliflozin advisory board of Merck & Co., Inc. (Kenilworth, NJ, USA). RF is an employee and shareholder of Pfizer Inc. MM is an employee of MSD UK, and may own stock and/or stock options in Merck & Co., Inc. (Kenilworth, NJ, USA). AP is an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (Kenilworth, NJ, USA) and may own stock and/or stock options in Merck & Co., Inc. (Kenilworth, NJ, USA). CPC reports grants and personal fees from Pfizer Inc. and from Merck & Co., Inc., during the conduct of the study. CPC also reports grants and personal fees from Amgen, Boehringer Ingelheim, Bristol-Myers Squibb and Janssen, grants from Better Therapeutics, Daiichi Sankyo Novo Nordisk, and personal fees from Aegerion/Amryt, Alnylam, Amarin, Applied Therapeutics, Ascendia, Corvidia, HLS Therapeutics, Innovent, Kowa, Sanofi, Eli Lilly, Lexicon, Rhoshan, and Sanofi outside the submitted work. CPC serves on Data and Safety Monitoring Boards for the Veterans Administration, Applied Therapeutics and Novo Nordisk. Funding Information: The authors would like to thank the participants, their families and all investigators involved in the VERTIS CV study; the list of investigators can be found with the primary publication []. Medical writing and/or editorial assistance was provided by M. Hammad and I. Norton, both of Scion (London, UK). This assistance was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., (Kenilworth, NJ, USA) and Pfizer Inc. (New York, NY, USA). Funding Information: Medical writing and/or editorial assistance for this letter was sponsored by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (Kenilworth, NJ, USA) and Pfizer Inc. (New York, NY, USA). The VERTIS CV study was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (Kenilworth, NJ, USA), in collaboration with Pfizer Inc. The sponsors were involved in the study design, collection, analysis and interpretation of data, as well as data checking of information provided in the manuscript. ",

year = "2022",

month = may,

doi = "10.1007/s00125-021-05623-z",

language = "English (US)",

volume = "65",

pages = "908--911",

journal = "Diabetologia",

issn = "0012-186X",

publisher = "Springer Verlag",

number = "5",

}

TY - JOUR

T1 - Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter]

AU - on behalf of the VERTIS CV Investigators

AU - Cherney, David Z.I.

AU - Charbonnel, Bernard

AU - Cosentino, Francesco

AU - Dagogo-Jack, Samuel

AU - McGuire, Darren K.

AU - Pratley, Richard

AU - Shih, Weichung J.

AU - Frederich, Robert

AU - Maldonado, Mario

AU - Pong, Annpey

AU - Cannon, Christopher P.

N1 - Funding Information: The authors would like to thank the participants, their families and all investigators involved in the VERTIS CV study; the list of investigators can be found with the primary publication [11]. Medical writing and/or editorial assistance was provided by M. Hammad and I. Norton, both of Scion (London, UK). This assistance was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., (Kenilworth, NJ, USA) and Pfizer Inc. (New York, NY, USA). DZIC has received consulting fees or speaking honorarium, or both, from Bristol-Myers Squibb, Novo Nordisk, Mitsubishis-Tanabe, MAZE, Janssen, Bayer, Boehringer Ingelheim, Eli Lilly, AstraZeneca, Merck & Co., Inc., Prometic and Sanofi, and has received operating funds from Janssen, Boehringer Ingelheim-Eli Lilly, Sanofi, AstraZeneca, Novo Nordisk and Merck & Co., Inc., Prometic and Sanofi, and has received operating funds from Janssen, Boehringer Ingelheim, Eli Lilly, Sanofi, AstraZeneca and Merck & Co., Inc. BC has received fees for the following activities: advisory boards for AstraZeneca, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (Kenilworth, NJ, USA), Novo Nordisk, Sanofi and Servier; and speaker bureau for AstraZeneca, Eli Lilly, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (Kenilworth, NJ, USA), Novo Nordisk, Sanofi and Takeda. FC has received fees from Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Merck Sharp & Dohme, Novo Nordisk and Pfizer, as well as research grants from Swedish Research Council, Swedish Heart & Lung Foundation and the King Gustav V and Queen Victoria Foundation. SD-J has led clinical trials for AstraZeneca, Novo Nordisk, Inc. and Boehringer Ingelheim, has received fees from AstraZeneca, Boehringer Ingelheim, Janssen, Merck & Co., Inc. and Sanofi, and holds equity interests in Jana Care, Inc. and Aerami Therapeutics. DKM has had leadership roles in clinical trials for AstraZeneca, Boehringer Ingelheim, CSL Behring, Eisai, Esperion, GlaxoSmithKline, Janssen, Lexicon, Merck & Co., Inc., Novo Nordisk and Sanofi USA, and has received consultancy fees from AstraZeneca, Bayer, Boehringer Ingelheim, Lilly USA, Merck & Co., Inc., Pfizer, Novo Nordisk, Metavant, Afimmune and Sanofi. RP has received the following fees (directed to his institution): speaker fees from Novo Nordisk; consulting fees from Merck & Co., Inc., Novo Nordisk, Pfizer, Sanofi, Scohia Pharma Inc. and Sun Pharmaceutical Industries; and grants from Lexicon Pharmaceuticals, Hanmi Pharmaceuticals Co., Novo Nordisk, Poxel SA and Sanofi. WJS has received fees for membership of the ertugliflozin advisory board of Merck & Co., Inc. (Kenilworth, NJ, USA). RF is an employee and shareholder of Pfizer Inc. MM is an employee of MSD UK, and may own stock and/or stock options in Merck & Co., Inc. (Kenilworth, NJ, USA). AP is an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (Kenilworth, NJ, USA) and may own stock and/or stock options in Merck & Co., Inc. (Kenilworth, NJ, USA). CPC reports grants and personal fees from Pfizer Inc. and from Merck & Co., Inc., during the conduct of the study. CPC also reports grants and personal fees from Amgen, Boehringer Ingelheim, Bristol-Myers Squibb and Janssen, grants from Better Therapeutics, Daiichi Sankyo Novo Nordisk, and personal fees from Aegerion/Amryt, Alnylam, Amarin, Applied Therapeutics, Ascendia, Corvidia, HLS Therapeutics, Innovent, Kowa, Sanofi, Eli Lilly, Lexicon, Rhoshan, and Sanofi outside the submitted work. CPC serves on Data and Safety Monitoring Boards for the Veterans Administration, Applied Therapeutics and Novo Nordisk. Funding Information: DZIC has received consulting fees or speaking honorarium, or both, from Bristol-Myers Squibb, Novo Nordisk, Mitsubishis-Tanabe, MAZE, Janssen, Bayer, Boehringer Ingelheim, Eli Lilly, AstraZeneca, Merck & Co., Inc., Prometic and Sanofi, and has received operating funds from Janssen, Boehringer Ingelheim-Eli Lilly, Sanofi, AstraZeneca, Novo Nordisk and Merck & Co., Inc., Prometic and Sanofi, and has received operating funds from Janssen, Boehringer Ingelheim, Eli Lilly, Sanofi, AstraZeneca and Merck & Co., Inc. BC has received fees for the following activities: advisory boards for AstraZeneca, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (Kenilworth, NJ, USA), Novo Nordisk, Sanofi and Servier; and speaker bureau for AstraZeneca, Eli Lilly, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (Kenilworth, NJ, USA), Novo Nordisk, Sanofi and Takeda. FC has received fees from Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Merck Sharp & Dohme, Novo Nordisk and Pfizer, as well as research grants from Swedish Research Council, Swedish Heart & Lung Foundation and the King Gustav V and Queen Victoria Foundation. SD-J has led clinical trials for AstraZeneca, Novo Nordisk, Inc. and Boehringer Ingelheim, has received fees from AstraZeneca, Boehringer Ingelheim, Janssen, Merck & Co., Inc. and Sanofi, and holds equity interests in Jana Care, Inc. and Aerami Therapeutics. DKM has had leadership roles in clinical trials for AstraZeneca, Boehringer Ingelheim, CSL Behring, Eisai, Esperion, GlaxoSmithKline, Janssen, Lexicon, Merck & Co., Inc., Novo Nordisk and Sanofi USA, and has received consultancy fees from AstraZeneca, Bayer, Boehringer Ingelheim, Lilly USA, Merck & Co., Inc., Pfizer, Novo Nordisk, Metavant, Afimmune and Sanofi. RP has received the following fees (directed to his institution): speaker fees from Novo Nordisk; consulting fees from Merck & Co., Inc., Novo Nordisk, Pfizer, Sanofi, Scohia Pharma Inc. and Sun Pharmaceutical Industries; and grants from Lexicon Pharmaceuticals, Hanmi Pharmaceuticals Co., Novo Nordisk, Poxel SA and Sanofi. WJS has received fees for membership of the ertugliflozin advisory board of Merck & Co., Inc. (Kenilworth, NJ, USA). RF is an employee and shareholder of Pfizer Inc. MM is an employee of MSD UK, and may own stock and/or stock options in Merck & Co., Inc. (Kenilworth, NJ, USA). AP is an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (Kenilworth, NJ, USA) and may own stock and/or stock options in Merck & Co., Inc. (Kenilworth, NJ, USA). CPC reports grants and personal fees from Pfizer Inc. and from Merck & Co., Inc., during the conduct of the study. CPC also reports grants and personal fees from Amgen, Boehringer Ingelheim, Bristol-Myers Squibb and Janssen, grants from Better Therapeutics, Daiichi Sankyo Novo Nordisk, and personal fees from Aegerion/Amryt, Alnylam, Amarin, Applied Therapeutics, Ascendia, Corvidia, HLS Therapeutics, Innovent, Kowa, Sanofi, Eli Lilly, Lexicon, Rhoshan, and Sanofi outside the submitted work. CPC serves on Data and Safety Monitoring Boards for the Veterans Administration, Applied Therapeutics and Novo Nordisk. Funding Information: The authors would like to thank the participants, their families and all investigators involved in the VERTIS CV study; the list of investigators can be found with the primary publication []. Medical writing and/or editorial assistance was provided by M. Hammad and I. Norton, both of Scion (London, UK). This assistance was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., (Kenilworth, NJ, USA) and Pfizer Inc. (New York, NY, USA). Funding Information: Medical writing and/or editorial assistance for this letter was sponsored by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (Kenilworth, NJ, USA) and Pfizer Inc. (New York, NY, USA). The VERTIS CV study was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (Kenilworth, NJ, USA), in collaboration with Pfizer Inc. The sponsors were involved in the study design, collection, analysis and interpretation of data, as well as data checking of information provided in the manuscript.

PY - 2022/5

Y1 - 2022/5

KW - Body weight

KW - Chronic kidney disease

KW - Ertugliflozin

KW - Estimated glomerular filtration rate

KW - Kidney outcomes

KW - Sodium–glucose cotransporter 2 inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85125573260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85125573260&partnerID=8YFLogxK

U2 - 10.1007/s00125-021-05623-z

DO - 10.1007/s00125-021-05623-z

M3 - Letter

C2 - 35238955

AN - SCOPUS:85125573260

SN - 0012-186X

VL - 65

SP - 908

EP - 911

JO - Diabetologia

JF - Diabetologia

IS - 5

ER -

Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter]

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this